SCYNEXIS’s mission is committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies.

They believe that their lead compound, Ibrexafungerp (formerly SCY-078), has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

[finviz ticker=SCYX link=true]